Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation for Female Cancer Patients (HKCH)

NCT06505057 | Recruiting

• 1 other identifier: PAED-2023-079
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Ovarian tissue freezing is an ideal option for these patients as it can be performed immediately and does not need any time for ovarian stimulation. We hope we can develop this service in our locality to allow more young female cancer patients to have their fertility preserved.

Conditions

Neoplasms

Outcome Measures

Primary Outcomes (1)

• Surgical complications

  Surgical complications after ovarian tissue transplantation

  15 years

Secondary Outcomes (1)

• Pregnancy rate

  15 years

Study Arms (1)

ovarian tissue freezing and subsequent auto-transplantation after thawing

EXPERIMENTAL

Removal of the ovarian tissue will be retrieved via laparoscopic surgery under general anesthesia. The ovarian cortical tissue obtained will be transferred on ice to the laboratory for cryopreservation. After medical treatment, if the patient would like to start a family but has experienced premature ovarian failure, she will have ovarian tissue auto-transplantation after thawing.

Other: Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation

Interventions

Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation OTHER

Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation

ovarian tissue freezing and subsequent auto-transplantation after thawing

Eligibility Criteria

• Age: 12 Years - 18 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Patients aged from 0-35 years old and diagnosed with cancer e.g., leukaemia, myeloproliferative or myelodysplastic diseases, lymphoma, bone tumours, neurological neoplasms and sarcoma, Paediatric bone marrow transplant patients
• Patients with any illness or who will undergo any type of treatment that may cause irreversible damage to their fertility, such as extensive abdominal surgery, high toxicity medication and treatments;
• Patients suffering from hormone-sensitive malignancies who will undergo medical treatment, such as radiotherapy and chemotherapy that is liable to damage their ovaries and deter them from conception in the future.

You may not qualify if:

• Patients with no anticipated oncologic therapies Patients who are pregnant Children with one ovary Children deemed high risk for perioperative complications Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)

Sponsors & Collaborators

• Chinese University of Hong Kong: lead

Study Sites (1)

Hong Kong Children's Hospital

Hong Kong, Hong Kong

RECRUITING

MeSH Terms

Conditions

Neoplasms

Study Officials

• Jacqueline Pui Wah CHUNG, MBBS

  Chinese University of Hong Kong

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Elaine NG, MPhil

CONTACT

35052745; elaineng@cuhk.edu.hk

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: July 11, 2024
• First Posted: July 17, 2024
• Study Start: August 13, 2024
• Primary Completion (Estimated): July 31, 2039
• Study Completion (Estimated): July 31, 2041
• Last Updated: January 8, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

HK (1)